The Effects of Somatostatin Analogues on HbA1c and BMI in the Treatment of Neuroendocrine Tumours
Introduction: Long acting somatostatin analogues (SSA) are the most commonly used drugs in the management of neuroendocrine tumours (NETs) due to their ability to control symptoms and prolong survival. SSAs use is associated with changes in glucose metabolism. However, there is lack of data for such effects in patients with NETs. We evaluated the effects of SSA on BMI and HbA1c in our cohort of patients with NETs.
Aim(s): Assess changes in glycaemic control before and after SSA treatment. Assess the incidence of new diabetes or whether there was worsening of diabetes control for patients with pre-existing diabetes and whether the duration of SSA treatment had any impact on glycaemic control.
Materials and methods: A retrospective study of 279 patients with NETs who are were treated with SSA. The study period was between January 2014 and January 2019. Glycaemic control was measured by changes in HbA1c and BMI. Populations were compared using the dependent t test.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Patel K
To read the full abstract, please log into your ENETS Member account.